Skip to main content
SpringerLink
Log in

Residual Recurrence Risk of Ischemic Cerebrovascular Events: Elements and Implications

  • Insight
  • Published:
Neuroscience Bulletin Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015, 372: 2387–2397.

    Article  CAS  Google Scholar 

  2. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017, 376: 1713–1722.

    Article  CAS  Google Scholar 

  3. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev 2019, 40: 537–557.

    Article  Google Scholar 

  4. van der Valk FM, Bekkering S, Kroon J, Yeang C, van den Bossche J, van Buul JD, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 2016, 134: 611–624.

    Article  Google Scholar 

  5. Puri R, Nissen SE, Arsenault BJ, John J, Riesmeyer JS, Ruotolo G, et al. Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: A prespecified secondary analysis of the ACCELERATE trial. JAMA Cardiol 2020, 5: 1136–1143.

    Article  Google Scholar 

  6. Viney NJ, van Capelleveen JC, Geary RS, Xia ST, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016, 388: 2239–2253.

    Article  CAS  Google Scholar 

  7. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013, 369: 11–19.

    Article  CAS  Google Scholar 

  8. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020, 383: 207–217.

    Article  CAS  Google Scholar 

  9. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016, 316: 70–78.

    Article  CAS  Google Scholar 

  10. Li J, Wang Y, Wang D, Lin J, Wang A, Zhao X, et al. Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. Neurology 2015, 84: 1330–1336.

    Article  CAS  Google Scholar 

  11. Li JJ, Wang YL, Li H, Zuo ZY, Lin JX, Wang AX, et al. Homocysteine level predicts response to dual antiplatelet in women with minor stroke or transient ischemic attack: Subanalysis of the CHANCE trial. Arterioscler Thromb Vasc Biol 2020, 40: 839–846.

    Article  CAS  Google Scholar 

  12. Li JJ, Wang AX, Zhao XQ, Liu LP, Meng X, Lin JX, et al. High-sensitive C-reactive protein and dual antiplatelet in intracranial arterial Stenosis. Neurology 2018, 90: e447–e454.

    Article  CAS  Google Scholar 

  13. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017, 377: 1319–1330.

    Article  CAS  Google Scholar 

  14. Korjian S, Braunwald E, Daaboul Y, Verheugt F, Bode C, Tendera M, et al. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care 2019, 8: 186–193.

    Article  Google Scholar 

  15. Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013, 127: 1404–1412.

    Article  Google Scholar 

  16. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359: 2195–2207.

    Article  CAS  Google Scholar 

  17. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017, 377: 1119–1131.

    Article  CAS  Google Scholar 

  18. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020, 383: 1838–1847.

    Article  CAS  Google Scholar 

  19. Alexander MJ, Zauner A, Chaloupka JC, Baxter B, Callison RC, Gupta R, et al. WEAVE trial: Final results in 152 on-label patients. Stroke 2019, 50: 889–894.

    Article  Google Scholar 

  20. Miao Z, Zhang Y, Shuai J, Jiang C, Zhu Q, Chen K, et al. Thirty-day outcome of a multicenter registry study of stenting for symptomatic intracranial artery Stenosis in China. Stroke 2015, 46: 2822–2829.

    Article  Google Scholar 

  21. Li JJ, Wang YJ. Blood biomarkers in minor stroke and transient ischemic attack. Neurosci Bull 2016, 32: 463–468.

    Article  CAS  Google Scholar 

  22. Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): A meta-analysis of genome-wide association studies. Lancet Neurol 2012, 11: 951–962.

    Article  Google Scholar 

  23. Williams FM, Carter AM, Hysi PG, Surdulescu G, Hodgkiss D, Soranzo N, et al. Ischemic stroke is associated with the ABO locus: The EuroCLOT study. Ann Neurol 2013, 73: 16–31.

    Article  Google Scholar 

  24. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Publisher Correction: Multiancestry genome-wide association study of 520, 000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 2019, 51: 1192–1193.

    Article  CAS  Google Scholar 

  25. Dichgans M, Pulit SL, Rosand J. Stroke genetics: Discovery, biology, and clinical applications. Lancet Neurol 2019, 18: 587–599.

    Article  Google Scholar 

  26. Cheng S, Xu Z, Liu Y, Lin JX, Jiang Y, Wang YL, et al. Whole genome sequencing of 10K patients with acute ischaemic stroke or transient ischaemic attack: Design, methods and baseline patient characteristics. Stroke Vasc Neurol 2020: svn–2020–000664.

  27. Gallego-Fabrega C, Carrera C, Reny JL, Fontana P, Slowik A, Pera J, et al. PPM1A methylation is associated with vascular recurrence in aspirin-treated patients. Stroke 2016, 47: 1926–1929.

    Article  CAS  Google Scholar 

  28. George PM, Mlynash M, Adams CM, Kuo CJ, Albers GW, Olivot JM. Novel TIA biomarkers identified by mass spectrometry-based proteomics. Int J Stroke 2015, 10: 1204–1211.

    Article  Google Scholar 

  29. Marklund M, Wu JHY, Imamura F, Del Gobbo LC, Fretts A, de Goede J, et al. Biomarkers of dietary Omega-6 fatty acids and incident cardiovascular disease and mortality. Circulation 2019, 139: 2422–2436.

    Article  CAS  Google Scholar 

  30. Montaner J, Ramiro L, Simats A, Tiedt S, Makris K, Jickling GC, et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol 2020, 16: 247–264.

    Article  Google Scholar 

Download references

Acknowledgements

This Insight was supported by grants from the National Key R&D Program of China(2018YFC1312903), a National Science and Technology Major Project (2017ZX09304018), the National Natural Science Foundation of China (81671128), the Beijing Municipal Administration of Hospitals’ Youth Programme (QML20190502), and the Young Scientist Program of Beijing Tiantan Hospital (YSP201702).

Author information

Author notes

  1. Jiejie Li and Zixiao Li have contributed equally to this Insight.

Authors and Affiliations

  1. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100075, China

    Jiejie Li, Zixiao Li & Yongjun Wang

  2. China National Clinical Research Center for Neurological Diseases, Beijing, 100075, China

    Tian-jie Lyu, Si Cheng, Yuehua Pu & Yongjun Wang

Authors
  1. Jiejie Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zixiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tian-jie Lyu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Si Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuehua Pu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yongjun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yongjun Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, J., Li, Z., Lyu, Tj. et al. Residual Recurrence Risk of Ischemic Cerebrovascular Events: Elements and Implications. Neurosci. Bull. 37, 1361–1364 (2021). https://doi.org/10.1007/s12264-021-00733-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-021-00733-5

Search

Navigation